Berg, D.
Eggert, K.
Haslinger, B.
Kassubek, J.
Mollenhauer, B.
Reetz, K.
Rogge, A.
Schaeffer, E.
Tönges, L.
Zeuner, K. E.
Article History
Received: 18 May 2020
Accepted: 25 June 2020
First Online: 2 November 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: D. Berg reports grants from Janssen Pharmaceutica, grants from the Damp foundation, grants from the German Parkinson’s Disease Association (dPV), grants from BMWi, grants from BMBF, grants from the ParkinsonFonds Deutschland GmbH, grants and speaker’s honoraria from and consultancy honoraria of UCB Pharma GmbH, grants and speaker’s honoraria from TEVA Pharma GmbH, grants from and consultancies for Novartis Pharma GmbH, grants and speaker’s honoraria from and consultancy honoraria of Lundbeck, speaker’s honoraria from and consultancy honoraria for BIAL, speaker’s honoraria from and consultancy honoraria for Biogen, honoraria from Bayer and Zambon outside the submitted work. K. Eggert receives funding from the German Parkinson Society, Abbvie, Acorda, Adamas, Addex, Apopharma,Benevolent, Bial, Biogen, Biotie, Impax, Kyowa, Mundipharma, Novartis, Orion, Pfizer, Roche. She receives advisory board fees from Bial, Grünenthal, Mundipharma and Zambon. She receives speaker fees from Bial, Desitin, Grünenthal, Mundipharma, UCB and Zambon. P. Haslinger reports grants from the Deutsche Forschungsgemeinschaft, he has served on a scientific advisory board for Merz and Bayer, has received speaker honoraria from Allergan and Ipsen and has received fees for clinical trials from Addex, Allergan, Apopharma, Bial, Biogen, Impax, Intec, Ipsen, Merz, Novartis, Pfizer, Revance and Sunovion. J. Kassubek has received personal consulting fees as an advisory board member and honoraria as a speaker from AbbVie, BIAL, Biogen, Boehringer Ingelheim, Desitin, Medtronic, NeuroDerm / Mitsubishi Tanabe Pharma, Novartis, Sunovion, TEVA Pharmaceuticals, UCB Pharma, and Zambon. He serves as a Section Chief Editor of Frontiers in Neurology. B. Mollenhauer has received honoraria for consultancy from Roche, Biogen, UCB and Sun Pharma Advanced research Company. She is member of the executive steering committee of the Parkinson Progression Marker Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson’s Research and has received research funding from the Deutsche Forschungsgemeinschaft (DFG), EU (Horizon2020), Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung and the Michael J. Fox Foundation for Parkinson’s Research. K. Reetz has received grants from the German Federal Ministry of Education and Research (BMBF 01GQ1402, 01DN18022), the German Research Foundation (IRTG 2150, ZUK32/1), Alzheimer Forschung Initiative e.V. (AFI 13812, NL-18002CB) and honoraria for presentations from Lilly and clinical trial grants from Pfizer, Merck, Minoryx, Biogen and Roche. A. Rogge has nothing to declare. E. Schaeffer received intramural research funding from the University of Kiel and speaker’s honoraria from Bayer Vital GmbH and Novartis, outside the submitted work. L. Tonges has received travel funding and/or speaker honoraria from Abbvie, Bayer, Bial, Desitin, GE, UCB, Zambon and consulted for Abbvie, Bayer, Bial, Desitin, UCB, Zambon in the last 3 years. K. E. Zeuner has received research support from an intramural grant from the Christian Albrechts-University of Kiel, from the Benign Essential Blepharospasm Foundation and with an unrestricted grant from Ipsen. She has received lecture fees from Allergan, Merz, AbbVie and Bayer. She has served as a consultant and received fees from Merz and Ipsen.